Phase 3 liver outcomes trial of tirzepatide and other drugs starts recruiting
A large outcomes trial in fatty liver disease could eventually show whether tirzepatide changes serious liver events, but its main results are not expected until 2030.
A phase 3 master protocol testing more than one drug in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) is now recruiting, with a target enrollment of 4,500 people and a primary endpoint built around major adverse liver outcomes [1]. Tirzepatide, sold as Mounjaro and Zepbound, is among the agents in the study [1].
The trial is listed on ClinicalTrials.gov as NCT07165028 and is named SYNERGY-Outcomes [1]. Its title describes it as a master protocol of multiple agents in adults with MASLD [1]. A master protocol tests more than one treatment inside a single overarching study structure instead of running a separate trial for each drug [1].
The primary measure is major adverse liver outcomes [1]. That kind of endpoint tracks serious liver-related events rather than only changes on a liver biopsy or in laboratory values. A trial built around outcomes answers a different question from one built around tissue or blood tests: whether a drug changes what happens to patients, not just how their liver tissue looks or how their numbers move.
Estimated primary completion is August 2030 [1]. That is when the last participant is expected to be measured for the primary endpoint. Results typically come later, and none have been posted [1].
Which agents besides tirzepatide are included in the protocol has not been reported, and neither has how many participants will receive each treatment. The study is listed as recruiting, so sites may be enrolling participants now [1].
The study shares the SYNERGY name with an earlier phase 2 trial, SYNERGY-NASH. Phase 2 studies can show whether a drug affects liver tissue, but they are not sized or designed to show whether it prevents serious liver outcomes. This phase 3 protocol is built around those outcomes, at a scale of 4,500 participants [1].
Why it matters for patients
For people living with MASLD or with MASH, the inflammatory form of the disease, the practical question is whether a medication lowers the risk of serious liver problems. Trials that measure major adverse liver outcomes are how that question gets answered, and they take years to run [1].
The estimated primary completion date of August 2030 means the trial will not produce its main answer for several years [1]. Treatment decisions made before then rest on evidence that already exists, not on this study's results, which have not been reported [1].
A master protocol allows several drugs to be evaluated under shared rules, which can make results easier to compare across agents than a set of separate trials would [1]. Tirzepatide is one of the agents included [1]; the full list of drugs in the protocol has not been reported.
People who want to take part would need to meet the study's eligibility criteria. Recruitment status alone does not mean a given person qualifies [1].
What happens next
Recruitment is open now [1]. The estimated primary completion date is August 2030 [1]. Under the registry's standard timeline, results are generally due within one year of that primary completion date [1]. No date for an interim analysis has been reported.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.